Trial · NCT05254808
EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
NCT05254808, Phase 3, Terminated, MJM Bonten
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care. Trials, record NCT05254808. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05254808
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
- NCT number
- NCT05254808
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 13 participants, actual
- Lead sponsor
- MJM Bonten
- Conditions
- Urinary Tract Infections
- Interventions
- Fosfomycin, Nitrofurantoin
- First posted
- 2022-02-24
- Last updated
- 2022-03-15
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to recovery | 28 days | Duration of absence of cystitis symptoms is defined as 'the number of days with full resolution of relevant cystitis symptoms, in the absence of aggravation to pyelonephritis or urosepsis within the period of 28 days after randomisation' |
| Secondary | Clinical failure | 28 days | Rate of clinical failure, defined as new or persisting cystitis symptoms or aggravation to pyelonephritis or urosepsis for which a new antibiotic treatment was prescribed within 28 days |
| Secondary | Microbiological failure | 28 days | Rate of microbiological failure at day 28 (26 to 31) defined as persistence of the initial infecting organism (≥ 103 colony forming units (cfu) /ml) |
| Secondary | Development of pyelonephritis or urosepsis | 28 days | Rate of pyelonephritis or urosepsis, defined as the occurrence of signs or symptoms of pyelonephritis or urosepsis (fever, flank pain, or other matching symptoms) for which antibiotic treatment was prescribed\* |
| Secondary | Relapse | 28 days | Rate of relapses at day 28, defined as clinical failure caused by the initial infecting organism (\> 103 cfu /ml) |
| Secondary | Reinfection | 28 days | Rate of reinfections at day 28, defined as clinical failure caused by another organism than the initial infecting organism |
| Secondary | All-cause mortality | 28 days | Rate of mortality (all-cause) |
| Secondary | All-cause hospital admission | 28 days | Rate of hospital admission (all-cause) |
| Secondary | Adverse events symptoms | 28 days | Duration of adverse events symptoms (including diarrhea, nausea, abdominal cramps, increased vaginal discharge or other). |
| Secondary | Incidence and nature of severe adverse events | 28 days |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05254808
GET https://conductscience.org/api/trials/v1/NCT05254808/registered